Clinlab Navigator


Zonisamide (Zonegran) is a sulfonamide anticonvulsant approved by the FDA for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic and generalized tonic clonic seizures.

Zonisamide is metabolized by the liver and excreted by the kidneys. Circulating half life is 30 to 60 hours.

Common adverse effects include sedation, dizziness, ataxia, weight loss and depression. Serious adverse effects include aplastic anemia, kidney stones, oligohydrosis, psychosis, and Stevens Johnson syndrome.

Therapeutic drug level is 10 to 40 ug/mL. Toxic side effects are uncommon at serum concentrations below 30 ug/mL. 

AddThis Social Bookmark Button